TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(U.S. dollars in millions, except for share data)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,697 | $3,300 |
| Accounts receivables, net of allowance for credit losses of $80 million and $78 million as of March 31, 2025 and December 31, 2024, respectively | 3,384 | 3,059 |
| Inventories | 3,247 | 3,007 |
| Prepaid expenses | 1,018 | 1,006 |
| Other current assets | 368 | 409 |
| Assets held for sale | 1,814 | 1,771 |
| Total current assets | 11,528 | 12,552 |
| Deferred income taxes | 1,762 | 1,799 |
| Other non-current assets | 464 | 462 |
| Property, plant and equipment, net | 4,631 | 4,581 |
| Operating lease right-of-use assets, net | 363 | 367 |
| Identifiable intangible assets, net | 4,189 | 4,418 |
| Goodwill | 15,477 | 15,147 |
| Total assets | $38,415 | $39,326 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Short-term debt | $421 | $1,781 |
| Sales reserves and allowances | 3,696 | 3,678 |
| Accounts payables | 2,290 | 2,203 |
| Employee-related obligations | 474 | 624 |
| Accrued expenses | 2,952 | 2,792 |
| Other current liabilities | 964 | 1,020 |
| Liabilities held for sale | 358 | 698 |
| Total current liabilities | 11,157 | 12,796 |
| Long-term liabilities: | ||
| Deferred income taxes | 461 | 483 |
| Other taxes and long-term liabilities | 4,011 | 4,028 |
| Senior notes and loans | 16,230 | 16,002 |
| Operating lease liabilities | 288 | 296 |
| Total long-term liabilities | 20,990 | 20,809 |
| Total liabilities | 32,146 | 33,606 |
| Redeemable non-controlling interests | — | 340 |
| Equity: | ||
| Teva shareholders’ equity: | ||
| Ordinary shares of NIS 0.10 par value per share; March 31, 2025 and December 31, 2024: authorized 2,495 million shares; issued 1,253 million shares and 1,240 million shares, respectively | 58 | 58 |
| Additional paid-in capital | 27,965 | 27,764 |
| Accumulated deficit | (14,958) | (15,173) |
| Accumulated other comprehensive loss | (2,675) | (3,148) |
| Treasury shares as of March 31, 2025 and December 31, 2024: 106 million ordinary shares | (4,128) | (4,128) |
| 6,262 | 5,373 | |
| Non-controlling interests | 7 | 7 |
| Total equity | 6,269 | 5,380 |
| Total liabilities, redeemable non-controlling interests and equity | $38,415 | $39,326 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.